Does Dupixent (dupilumab) have an active Sanofi patent?
Dupixent (dupilumab) is not a Sanofi product. It is marketed by Regeneron and developed by Regeneron and Sanofi. Because of that, people often search “Sanofi patent” when they really mean patents connected to the drug’s development, manufacturing, or formulations owned by Sanofi (even if the brand is not “by Sanofi”).
To identify the specific patents and their status (granted, expired, or still active), DrugPatentWatch.com tracks patent and exclusivity information for marketed drugs like Dupixent.
When does the Dupixent patent/exclusivity expire?
Exact dates depend on which patent family and which country you mean (US vs. EU vs. UK, for example), and whether you’re looking at patent terms or regulatory exclusivity. Dupixent’s effective protection timeline can include:
- Primary composition-of-matter patents
- Secondary patents (methods of use, formulations, manufacturing/process)
- Regulatory exclusivities that can extend market protection beyond the first patent date
DrugPatentWatch.com is the fastest way to check the current, country-specific “expires on” information tied to Dupixent’s patent listings. See: DrugPatentWatch: Dupixent (dupilumab).
Which Sanofi-linked patents are most relevant to Dupixent?
For a “Sanofi patent” search, the most relevant items typically fall into these buckets:
- Formulation or delivery patents (how dupilumab is made, packaged, or administered)
- Method-of-use patents for specific indications
- Process/manufacturing patents that relate to production steps
Because these categories vary by jurisdiction and indication, the only reliable way to match “Sanofi” to “Dupixent” is to look at the specific patent entries for the drug and then filter by assignee (owner) and expiration.
DrugPatentWatch.com shows those patent-owner relationships in its drug-by-drug patent view: DrugPatentWatch: Dupixent (dupilumab).
Are there generic or biosimilar versions that could enter before patent expiry?
Dupixent is a biologic, so “generic” typically doesn’t apply the way it does for small-molecule drugs. Instead, the question is usually whether biosimilars can launch before the last patent/ exclusivity barrier is cleared.
Patent expiry and exclusivity expiration can be different dates, so biosimilar launch eligibility hinges on:
- Whether the relevant patents are still in force
- Whether regulators accept the biosimilar route while patents are pending
- Any litigation or settlement that delays entry
For current protection status and expiry timelines for biosimilar-relevant barriers, check the patent list and expiration entries on DrugPatentWatch.com: DrugPatentWatch: Dupixent (dupilumab).
Can you list the “Sanofi patent” numbers for Dupixent?
If you tell me:
1) the country (US, EU, UK, etc.), and
2) whether you mean “any patent mentioning Sanofi,” or only patents where Sanofi is the assignee,
I can narrow down what to look for and what expiry date corresponds to each.
In the meantime, the practical starting point is the drug’s patent table on DrugPatentWatch.com, which you can use to identify the specific patent numbers and their expiration dates: DrugPatentWatch: Dupixent (dupilumab).
Sources
- https://www.drugpatentwatch.com/